» Articles » PMID: 18977641

In Vitro Susceptibility of Established Biofilms Composed of a Clinical Wound Isolate of Pseudomonas Aeruginosa Treated with Lactoferrin and Xylitol

Overview
Date 2008 Nov 4
PMID 18977641
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The medical impact of bacterial biofilms has increased with the recognition of biofilms as a major contributor to chronic wounds such as diabetic foot ulcers, venous leg ulcers and pressure ulcers. Traditional methods of treatment have proven ineffective, therefore this article presents in vitro evidence to support the use of novel antimicrobials in the treatment of Pseudomonas aeruginosa biofilm. An in vitro biofilm model with a clinical isolate of P. aeruginosa was subjected to treatment with either lactoferrin or xylitol alone or in combination. Combined lactoferrin and xylitol treatment disrupted the structure of the P. aeruginosa biofilm and resulted in a >2log reduction in viability. In situ analysis indicated that while xylitol treatment appeared to disrupt the biofilm structure, lactoferrin treatment resulted in a greater than two-fold increase in the number of permeabilised bacterial cells. The findings presented here indicated that combined treatment with lactoferrin and xylitol significantly decreases the viability of established P. aeruginosa biofilms in vitro and that the antimicrobial mechanism of this treatment includes both biofilm structural disruption and permeablisation of bacterial membranes.

Citing Articles

Real-time acid production and extracellular matrix formation in mature biofilms of three strains with special reference to xylitol.

Ikalainen H, Guzman C, Saari M, Soderling E, Loimaranta V Biofilm. 2024; 8:100219.

PMID: 39281714 PMC: 11402442. DOI: 10.1016/j.bioflm.2024.100219.


Lactoferrin Affects the Viability of Bacteria in a Biofilm and the Formation of a New Biofilm Cycle of A2.

Ruiz-Mazon L, Ramirez-Rico G, de la Garza M Int J Mol Sci. 2024; 25(16).

PMID: 39201405 PMC: 11355051. DOI: 10.3390/ijms25168718.


Effect of Xylitol on Inhibition and Eradication of Pseudomonas aeruginosa PAO1 and Methicillin-Resistant Staphylococcus aureus Biofilms in an Alginate Bead Model.

Siroosi M, Jabalameli F Curr Microbiol. 2024; 81(9):272.

PMID: 39014046 DOI: 10.1007/s00284-024-03799-2.


A Review on cLF36, a Novel Recombinant Antimicrobial Peptide-Derived Camel Lactoferrin.

Morovati S, Baghkheirati A, Sekhavati M, Razmyar J Probiotics Antimicrob Proteins. 2024; 16(5):1886-1905.

PMID: 38722550 DOI: 10.1007/s12602-024-10285-5.


Manganese Acts as an Environmental Inhibitor of Pseudomonas aeruginosa Biofilm Development by Inducing Dispersion and Modulating c-di-GMP and Exopolysaccharide Production via RbdA.

Park S, Dingemans J, Sauer K J Bacteriol. 2023; 205(6):e0000323.

PMID: 37199658 PMC: 10294637. DOI: 10.1128/jb.00003-23.


References
1.
Weinberg E . Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol. 2001; 53(10):1303-10. DOI: 10.1211/0022357011777792. View

2.
. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008; 31(3):596-615. DOI: 10.2337/dc08-9017. View

3.
Valenti P, Berlutti F, Conte M, Longhi C, Seganti L . Lactoferrin functions: current status and perspectives. J Clin Gastroenterol. 2004; 38(6 Suppl):S127-9. DOI: 10.1097/01.mcg.0000128941.46881.33. View

4.
Vogel L, Geluk F, Jansen H, Dankert J, van Alphen L . Human lactoferrin receptor activity in non-encapsulated Haemophilus influenzae. FEMS Microbiol Lett. 1997; 156(1):165-70. DOI: 10.1111/j.1574-6968.1997.tb12723.x. View

5.
Kim J, Pitts B, Stewart P, Camper A, Yoon J . Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. Antimicrob Agents Chemother. 2008; 52(4):1446-53. PMC: 2292569. DOI: 10.1128/AAC.00054-07. View